Rationally designed approaches to augment CAR-T therapy for solid tumor treatment
Source abstract
Abstract
Chimeric antigen receptor T cell denoted as CAR-T therapy has realized incredible therapeutic advancements for B cell malignancy treatment. However, its therapeutic validity has yet to be successfully achieved in solid tumors. Different from hematological cancers, solid tumors are characterized by dysregulated blood vessels, dense extracellular matrix, and filled with immunosuppressive signals, which together result in CAR-T cells’ insufficient infiltration and rapid dysfunction. The insufficient recognition of tumor cells and tumor heterogeneity eventually causes cancer reoccurrences. In addition, CAR-T therapy also raises safety concerns, including potential cytokine release storm, on-target/off-tumor toxicities, and neuro-system side effects. Here we comprehensively review various targeting aspects, including CAR-T cell design, tumor modulation, and delivery strategy. We believe it is essential to rationally design a combinatory CAR-T therapy via constructing optimized CAR-T cells, directly manipulating tumor tissue microenvironments, and selecting the most suitable delivery strategy to achieve the optimal outcome in both safety and efficacy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: CAR-T cell therapy research · Nanowire Synthesis and Applications · Virus-based gene therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Cancer immunotherapy comes of age10.1038/nature10673 ↗
2. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia10.1126/scitranslmed.3008226 ↗
3. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy10.1038/nrclinonc.2016.25 ↗
4. Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice10.1073/pnas.1903854116 ↗
5. Engineering strategies to overcome the current roadblocks in CAR T cell therapy10.1038/s41571-019-0297-y ↗
6. The principles of engineering immune cells to treat cancer10.1016/j.cell.2017.01.016 ↗
7. From bench to bedside: the history and progress of CAR T cell therapy10.3389/fimmu.2023.1188049 ↗
8. CAR T cells in solid tumors: challenges and opportunities10.1186/s13287-020-02128-1 ↗
9. Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma10.1126/scitranslmed.abd6169 ↗
10. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial10.1038/s41591-022-01726-1 ↗
11. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia10.1056/NEJMoa1709919 ↗
12. Delivery techniques for enhancing CAR T cell therapy against solid tumors10.1002/adfm.202009489 ↗
13. CAR T cell therapy: a game changer in cancer treatment10.1155/2016/5474602 ↗
14. Genetic engineering of T cells for immunotherapy10.1038/s41576-021-00329-9 ↗
15. Engineering-enhanced CAR T cells for improved cancer therapy
16. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity10.1073/pnas.86.24.10024 ↗
17. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells10.1073/pnas.91.10.4318 ↗
18. Programming CAR-T cells to kill cancer10.1038/s41551-018-0235-9 ↗
19. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor10.1038/nbt0102-70 ↗
20. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia10.1038/sj.leu.2403302 ↗
21. Engineered T cells: the promise and challenges of cancer immunotherapy10.1038/nrc.2016.97 ↗
22. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma10.1111/imr.12125 ↗
23. Human memory T cells: generation, compartmentalization and homeostasis10.1038/nri3567 ↗
24. T STEM -like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models10.1126/scitranslmed.abk1900 ↗
25. CAR-T cell therapy: current limitations and potential strategies10.1038/s41408-021-00459-7 ↗
26. Reassessing target antigens for adoptive T-cell therapy10.1038/nbt.2725 ↗
27. CAR-T – and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving CAR-T cell therapy10.1016/j.blre.2019.100596 ↗
28. Designing chimeric antigen receptors to effectively and safely target tumors10.1016/j.coi.2015.01.002 ↗
29. Optimizing EphA2-CAR T cells for the adoptive immunotherapy of glioma10.1016/j.omtm.2018.01.009 ↗
30. Design and development of therapies using chimeric antigen receptor-expressing T cells10.1111/imr.12131 ↗
31. The optimal antigen response of chimeric antigen receptors harboring the CD3ζ transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex
32. CD3ζ-based chimeric antigen receptors mediate T cell activation via cis - and trans -signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy10.1111/cei.12216 ↗
33. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation10.1182/blood-2004-09-3737 ↗
34. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains10.1038/s41571-021-00530-z ↗
35. Killing mechanisms of chimeric antigen receptor (CAR) T cells10.3390/ijms20061283 ↗
36. Granzymes, cytotoxic granules and cell death: the early work of Dr. Jurg Tschopp10.1038/cdd.2011.156 ↗
37. Mechanisms of granule-dependent killing10.1038/sj.cdd.4402244 ↗
38. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ10.1158/0008-5472.CAN-14-0079 ↗
39. CAR-T cells hit the tumor microenvironment: strategies to overcome tumor escape10.3389/fimmu.2020.01109 ↗
40. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid10.1038/s41586-020-03045-2 ↗
41. Inhibitory effect of tumor cell–derived lactic acid on human T cells10.1182/blood-2006-07-035972 ↗
42. T cell dysfunction in cancer immunity and immunotherapy10.3389/fimmu.2019.01719 ↗
43. Tumor antigen escape from CAR T-cell therapy10.1158/2159-8290.CD-18-0442 ↗
44. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors10.1126/sciadv.abi5781 ↗
45. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor10.1038/nbt.4086 ↗
46. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes10.1038/nm.3833 ↗
47. The vascular disrupting agent CA4P improves the antitumor efficacy of CAR-T cells in preclinical models of solid human tumors10.1016/j.ymthe.2019.10.010 ↗
48. Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade10.1016/j.ccell.2020.11.005 ↗
49. Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells
50. Recent advances of nanotechnology-facilitated bacteria-based drug and gene delivery systems for cancer treatment10.3390/pharmaceutics13070940 ↗
51. Engineered bacteria for augmented in situ tumor vaccination10.1039/D2BM01593E ↗
52. Live attenuated bacterium limits cancer resistance to CAR-T therapy by remodeling the tumor microenvironment10.1136/jitc-2021-003760 ↗
53. Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor10.1126/science.aav8692 ↗
54. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors10.1126/science.aay5967 ↗
55. Cell delivery devices for cancer immunotherapy10.1016/j.jconrel.2022.11.041 ↗
56. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity10.1126/scitranslmed.3010162 ↗
57. Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma10.1126/sciadv.abg5841 ↗
58. Nitinol thin films functionalized with CAR-T cells for the treatment of solid tumours10.1038/s41551-019-0486-0 ↗
59. Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy10.1093/nsr/nwab172 ↗
60. Chimeric antigen receptor signaling: functional consequences and design implications10.1126/sciadv.aaz3223 ↗
61. Wu W, Zhou Q, Masubuchi T, Shi X, Li H, Xu X, Huang M, Meng L, He X, Zhu H, Gao S, Zhang N, Jing R, Sun J, Wang H, Hui E, Wong CC, Xu C. Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy, Cell. 182 (2020) 855-871.10.1016/j.cell.2020.07.018 ↗
62. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling10.1126/scisignal.aay8248 ↗
63. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies10.1089/hum.2009.122 ↗
64. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell–mediated tumor eradication10.1038/mt.2009.210 ↗
65. A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity10.1126/scitranslmed.aba7308 ↗
66. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo10.1038/nbt.4195 ↗
67. Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy10.1016/j.omto.2021.03.014 ↗
68. A2A adenosine receptor protects tumors from antitumor T cells10.1073/pnas.0605251103 ↗
69. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor10.1007/s00262-011-1155-7 ↗
70. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy10.1038/s41467-021-23331-5 ↗
71. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors10.1038/s41423-021-00749-x ↗
72. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL10.1038/s41586-022-05140-y ↗
73. Nanomodulators targeting tumor-resident immunosuppressive cells: mechanisms and recent updates10.1016/j.nantod.2022.101641 ↗
74. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma10.1038/s41467-020-20599-x ↗
75. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer10.1002/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M ↗
76. A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia10.1126/scitranslmed.abg6986 ↗
77. An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma10.1126/scitranslmed.abg7565 ↗
78. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies10.1126/scitranslmed.abg3072 ↗
79. Oncolytic viruses in cancer treatment: a review10.1001/jamaoncol.2016.2064 ↗
80. Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy10.1038/s41417-021-00359-9 ↗
81. Inhibition of tumor metastasis by liquid‐nitrogen‐shocked tumor cells with oncolytic viruses infection10.1002/adma.202370197 ↗
82. Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer10.1016/j.ymthe.2017.09.010 ↗
83. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity10.1016/j.ymthe.2021.02.004 ↗
84. Biopolymer implants enhance the efficacy of adoptive T-cell therapy10.1038/nbt.3104 ↗
85. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets10.1038/s41551-021-00712-1 ↗
86. Clinical implications of intratumor heterogeneity: challenges and opportunities10.1007/s00109-020-01874-2 ↗
87. Driving CARs on the uneven road of antigen heterogeneity in solid tumors10.1016/j.coi.2018.03.002 ↗
88. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial10.1038/s41591-021-01436-0 ↗
89. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy10.1182/blood-2018-11-883710 ↗
90. Engineering customized cell sensing and response behaviors using synthetic notch receptors10.1016/j.cell.2016.01.012 ↗
91. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits10.1016/j.cell.2016.01.011 ↗
92. Logic-gated ROR1 chimeric antigen receptor expression rescues T CellMediated toxicity to normal tissues and enables selective tumor targeting10.1016/j.ccell.2019.02.003 ↗
93. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma10.1126/scitranslmed.abe7378 ↗
94. Intratumoral immunotherapy: using the tumor as the remedy10.1093/annonc/mdx683 ↗
95. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity10.1038/s41590-020-0676-7 ↗
96. CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers10.1038/s41551-022-00875-5 ↗
97. Engineering CAR-T cells to activate small-molecule drugs in situ10.1038/s41589-021-00932-1 ↗
98. CAR-T cells SEAK help from enzymes10.1038/s41589-021-00933-0 ↗
99. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function10.1016/j.cell.2021.08.004 ↗
100. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors10.1126/scitranslmed.aaz1863 ↗